Manual of Commercial Methods in Clinical Microbiology 2016
DOI: 10.1002/9781119021872.ch13
|View full text |Cite
|
Sign up to set email alerts
|

Commercial Methods for Identification and Susceptibility Testing of Fungi

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
3
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 304 publications
0
3
0
Order By: Relevance
“…Rapid tests identification of opportunistic fungal pathogens in immunocompromised children and those with HIV or solid organ transplants: Quick TAT as compaed with culture 22Direct testing of CSF (latex agglutination test on a card), enzyme immunoassays for serum/CSF or point-of-care test (POCT) strip test (lateral flow assay akin to pregnancy strip tests) for cryptococcal antigen.Rapid identification of positive fungal growth from sputum, bronchioalveolar lavage, CSF and body fluids/pus/tissues by automated systems (molecular PCR for 18 s/5.8 s rDNA subunit or internal transcribed spacer of the fungus)—this can be targeted directly on normally sterile specimens, but methods are not validated or standardised completely yet.Protein-based identification by MALDI-ToF/MS or rapid conventional biochemical methods.Molecular testing (Accuprobe R ) for dimorphic fungi—has been Food and Drug Administration approved for use in the USA.Multiplex PCR technology (Luminex R ) for most common clinically relevant fungal pathogens (7-plex or 11-plex panels) is currently being explored/evaluated for rapid TAT and simultaneous detection of mixed infections. …”
Section: Introductionmentioning
confidence: 99%
“…Rapid tests identification of opportunistic fungal pathogens in immunocompromised children and those with HIV or solid organ transplants: Quick TAT as compaed with culture 22Direct testing of CSF (latex agglutination test on a card), enzyme immunoassays for serum/CSF or point-of-care test (POCT) strip test (lateral flow assay akin to pregnancy strip tests) for cryptococcal antigen.Rapid identification of positive fungal growth from sputum, bronchioalveolar lavage, CSF and body fluids/pus/tissues by automated systems (molecular PCR for 18 s/5.8 s rDNA subunit or internal transcribed spacer of the fungus)—this can be targeted directly on normally sterile specimens, but methods are not validated or standardised completely yet.Protein-based identification by MALDI-ToF/MS or rapid conventional biochemical methods.Molecular testing (Accuprobe R ) for dimorphic fungi—has been Food and Drug Administration approved for use in the USA.Multiplex PCR technology (Luminex R ) for most common clinically relevant fungal pathogens (7-plex or 11-plex panels) is currently being explored/evaluated for rapid TAT and simultaneous detection of mixed infections. …”
Section: Introductionmentioning
confidence: 99%
“…Recommended techniques for antifungal susceptibility testing of molds are the reference techniques of CLSI and EUCAST. The gradient concentration strip method has shown good correlation with the reference techniques for yeasts and filamentous fungi (28). Nevertheless, only a few studies evaluated the correlation between gradient concentration strips and CLSI (14,(16)(17)(18)(19)(20)(21)(22) or EUCAST (13,15) methodology for Mucorales species.…”
mentioning
confidence: 99%
“…Recently, several clinical evaluations to detect Aspergillus DNA, either in respiratory or in blood-based samples, have clearly shown the diagnostic value of this biomarker (4)(5)(6)(7)(8)(9). In addition, methodological recommendations have been established for PCR protocols (10), and different standardized Aspergillus quantitative PCR (qPCR) kits have been commercialized (11,12). These recent advances show that PCR is now mature for routine use in clinical settings.…”
mentioning
confidence: 99%